Florida Woman Sues Novo Nordisk Over Ozempic Vision Loss After 2 Years of Use
Updated
Updated · AboutLawsuits.com · Aug 3
Florida Woman Sues Novo Nordisk Over Ozempic Vision Loss After 2 Years of Use
2 articles · Updated · AboutLawsuits.com · Aug 3
Summary
July 28 court filings in Pennsylvania say Caryn Schollmeyer used Ozempic from September 2019 to January 2021 and then suffered sudden, permanent vision loss diagnosed as NAION.
The lawsuit alleges Novo Nordisk failed to warn patients and doctors about the optic-nerve risk even after updating Ozempic's label at least 13 times since 2017, most recently in January 2025.
A July 2024 study cited in the complaint linked Ozempic and Wegovy to a sevenfold higher NAION risk than other drugs, helping spur dozens of similar vision-loss suits over GLP-1 medicines.
Schollmeyer's case will join the Ozempic NAION multidistrict litigation in the Eastern District of Pennsylvania, where coordinated discovery is expected before any bellwether trials or settlement talks.